Index

Note: Page numbers of article titles are in **boldface** type.

ACCIDENTS, obstetric, leading to haemorrhage, 166
Acidaemia in the neonate, 63
Acid—base balance, disturbances of in hyaline membrane disease, 61-64
Acidosis, correction of, 76-78
  metabolic, 281-283
    derived from amino acid metabolism, 282
    derived from carbohydrate metabolism, 282-283
Adenosine deaminase deficiency, screening for in the newborn, 279
Adipose tissue, brown, fetal development of, 47-48
Adrenocorticotrophin (ACTH), in the neonate, 228-230
Agar, in the treatment of hyperbilirubinaemia, 116
Alanine, in the newborn, 279
Alcohols, availability of as nutrient materials, 202-203
Aldosterone, in neonatal electrolyte metabolism, 15-18
Alkaline phosphatase, during pregnancy, 132
Alpha-1-antitrypsin deficiency, screening for in the newborn, 277
Aminoacidopathies in the newborn, detection of by chromatography, 279-281
Amino acids, requirements of for parenteral nutrition, 197-198
Amino acid solutions, availability of as nutrient materials, 205-208
Aminoglycosides, in the fetus and newborn, 184-185
Amniotic fluid, concentrations of electrolytes in, 124, 125
Anaemia, iron deficiency, clinical aspects of, 164-170
  aetiology of, 164
  due to congenital atransferrinaemia, 167-170
  due to intranatal blood loss, 165-166
  due to postnatal blood loss, 166-167
  due to prenatal blood loss, 164-165
Anencephalic fetuses, insulin levels in, 248
Angiotensin, in neonatal electrolyte metabolism, 15-18
Antibiotics—
  for use with parenteral feeding, 212-213
  in the fetus and newborn, 182-185
Anticonvulsants, in the fetus and newborn, 186-187
Antidiuretic hormone (ADH), *see under* Vasopressin
Arginine, in the newborn, 279-280
Argininosuccinic acid, in the newborn, 279-280
Asphyxia, perinatal, effects of on electrolyte metabolism, 141
Atransferrinaemia, congenital, 167-170

BILIRUBIN—
  free, in kernicterus, 119-120
  in infants of diabetic mothers, 247
  metabolism of in the neonate in relation to jaundice, **107-122**
  photodecomposition of in vitro, 113-114
  photodecomposition of in vivo, 114-116
Birth injury, effects of on electrolyte metabolism, 141
Blood—
  concentrations of electrolytes in, in the mother, 123-124
  content of electrolytes in the fetus, 126-130
  gases, in infants of diabetic mothers, 246-247
  products, availability as nutrient materials, 208-210
  proteins in the neonate, in hyaline membrane disease, 64
  volume in the neonate—
    effect on renal function, 8
    following caesarean section, 6
    idiopathic respiratory distress syndrome and, 6-7
    in hyaline membrane disease, 64
Body temperature in the neonate, in hyaline membrane disease, 65-67
Body water—
  compartmentation of, 3-5
  in infants of diabetic mothers, 243
Bowel, bleeding from, 166-167

Breast milk jaundice, 116-119
epidemiology of, 118
in vitro studies of, 116-118
metabolic fuels involved in, 119
Brown adipose tissue, fetal development of, 47-48

CAESAREAN section, blood volume following, 6
Calcitonin—
during pregnancy, 134-135
in infants of diabetic mothers, 250
Calcium metabolism in the perinatal period, **123-147**
disturbed, 135-143
classification of, 136
clinical management of, 135-136
effects of prematurity and intrauterine growth retardation on, 140-141
from inherent defects in parents, 136-137
impairment of placental function and, 140
intrauterine mineral status and, 137-138
nutritional deficiency and, 138-140
treatment of, 141-142
in infants of diabetic mothers, 246
neonatal requirements, 131
normal maternal requirements, 123-135
amniotic fluid concentration, 125
blood concentrations, 123-124
fetal content of, 125-130
hormonal aspects of, 131-135
placental concentrations, 124
transplacental movement of, 125
Carbohydrates—
availability of as nutrient material, 202
in infants of diabetic mothers, 243-244
blood glucose level and behaviour in, 243-244
glucose tolerance of, 244
glycogen in, 244
requirements of for parenteral nutrition, 197
Cardiac glycosides, in the fetus and newborn, 185-186
Catecholamines, in infants of diabetic mothers, 249
Catalase, role of iron in the action of, 150
Catheter care, with parenteral nutrition, 211-212
Cephalosporins, in the fetus and newborn, 183-184
Cerebrospinal fluid, fetal, electrolyte content of, 130
C'1-esterase inhibition, screening for in the newborn, 277
Chromatographic methods for metabolic screening of the newborn, 271, 279-281
Citrate, metabolism of in the newborn, 231-232
Citrulline, in the newborn, 279-280
CNS damage, resulting from hyaline membrane disease, 68-69
Coagulation—
defects in, in the full-term infant, 104-105
defects in, in the preterm infant, 104-105
defects in the neonate, **89-106**
disturbed as a result of pathological states, 97-104
factors, 90-91, 96
estimation of, 92-94
Coagulopathy, disseminated intravascular, 167
Compartmentation of body water, 3-5
Congenital atransferrinaemia, 167-170
clinical manifestations of, 167-168
diagnosis of, 168-169
treatment of, 169-170
Congenital plasma factor deficiency, 167
Conn's syndrome, 17
Conservation of water, in the neonate, 13-14
Consumption coagulopathy, 100-102, 167
investigations of, 101-102
pathogenesis of, 101
treatment of, 102
Corticosteroids, in infants of diabetic mothers, 249
Creatine phosphokinase (CPK), screening for in the newborn, 277
Cystathioninuria, 280
Cystic fibrosis, screening test for, 283
Cytochromes, role of iron in, 150

DEHYDRATION, isotonic, in the newborn, 30
Diabetes, insipidus, 20-21
congenital nephrogenic, 20-21
vasopressin-sensitive, 20
maternal, effects of on the infant, **237-264**
at birth, 251-252
biochemical features of, 243-247
clinical features of, 238-242
behaviour, 239-242
morphology, 238-239
hormonal changes, 247-250
maturational, 252
on maternal health, 251
pathology, 250-251
treatment of, 255-259
natal, 257
postnatal, 257-259
prenatal, 255-257
Di George syndrome, 137
Dinitrophenylhydrazine test, for screening in the newborn, 272-273
Disseminated intravascular coagulopathy, *see under* Consumption coagulopathy
Disseminated intravascular coagulation, initiated by hyaline membrane disease, 68

Diuretics, in the fetus and newborn, 187
Drugs, in the fetus and newborn, **175-190**
absorption of, 175-176
development of drug metabolising capacity, 179-181
distribution of, 177
excretion of, 181-182
metabolism of, 177-178
non-synthetic reactions with, 178
specific groups of, 182-187
synthetic reactions with, 179
Dyspnoea, management of in infants of diabetic mothers, 258

ELECTROLYTE metabolism—
in infants of diabetic mothers, 246-247
in the newborn infant, **3-37**
in the perinatal period, **123-147**
Enzymic assays, for metabolic screening of the newborn, 271
Endocrinology of the neonate, as studied by exchange transfusion, **221-235**
Erythropoietic activity, in the marrow, 162
Exchange transfusion—
in the study of neonatal metabolism and endocrinology, **221-235**
temperature changes during, 232-233
Excreta, fetal, electrolyte content of, 130
Excretion—
of iron, 163
of sodium, 11-13
of water, 13-14

FAT, requirements of for parenteral nutrition, 197
Fat emulsions, availability of as nutrient materials, 203-205
Fatty acids—
in infants of diabetic mothers, 245
metabolism of in the neonate, 222-227
Feeding, intravenous, of the newborn, **191-219**
Ferric chloride test, for screening the newborn, 272
Fetal content of electrolytes, 125-130
in blood, 126-130
correlations, 129-130
in cerebrospinal fluid, 130
in excreta, 130
in muscle, 130
iron, 151-153
total, 125-126
Fetal development of brown adipose tissue, 47-48
Fetal iron, interchange with maternal, 155-158
Fetal relation to maternal iron nutrition, 153-155
Fetal renal function, 9-11
Fetal rickets, 139-140
Fetus, drugs in, **175-190**
absorption of, 175-176
development of drug metabolising capacity, 179-180
distribution of, 177
excretion of, 181-182
metabolism of, 177-178
non-synthetic reactions with, 178
specific groups, 182-187
synthetic reactions with, 179
Fibrinolysis, 95, 96
Fluid balance requirements, 8-9
Fluid maintenance requirements, 8-9
Fluid metabolism in the newborn infant, **3-37**
in hyaline membrane disease, 65
Folic acid deficiency, thrombocytopenia from, 100
Food, iron content of, 159-160
Fructose 1,6-diphosphatase deficiency, 283

GALACTOKINASE, deficiency of in the newborn, 275
Galactosaemia, in the newborn, 275-276
Galactose, screening for in the newborn, 275-276
Glomerular filtration in the neonate, 11
Glucose-6-phosphate dehydrogenase deficiency, screening for in the newborn, 277-278
Glucagon, in the neonate, 222-227
in infants of diabetic mothers, 249
Glucocorticoids, in the neonate, 228-230
Glucose, metabolism of in the neonate, 222-227
Glucose tolerance test, in infants of diabetic mothers, 244
Glutamine in the newborn, 279-280
Glycine, in the newborn, 279
Glycosides, cardiac, in the fetus and newborn, 185-186
Growth hormone (GH), in the neonate, 227-228
in infants of diabetic mothers, 249
Growth retardation, intrauterine, effects of on electrolyte metabolism, 140-141

HAEMOGLOBIN, role of iron in, 149
Haemoglobinopathies, screening for in the newborn, 278
Haemorrhage—
intraplacental, 165

Haemorrhage—*continued*
intraventricular, 103-104
pulmonary, 102-103
retro-placental, 165
transplacental, 164
Haemostasis—
disturbed as a result of pathological states, 97-104
in normal mature infants, 89-95
in preterm and low birth weight infants, 95-96
methods of investigation, 96-97
Hartnup disease, 280
Hepatic immaturity, 167
Heterothermy in the newborn, 39-40
Histidine, screening for in the newborn, 274-275
Homocystinuria, screening for in the newborn, 275
Homeothermy in the newborn, 39-40
Hyaline membrane disease (HMD)—
metabolic aspects of treatment of, 69-79
induction of surfactant, 70-72
prediction of, 69-70
prognosis of, 78-79
treatment of, 73-78
metabolic consequences of, 60-69
metabolic setting for, 55-60
aetiological factors in, 58-60
surfactant and surfactant deficiency in, 56-58
Hydroxyproline, in the newborn, 280
Hyperaldosteronism, 16-18
primary, 17
pseudo-, 17
secondary, 17-18
Hyperbilirubinaemia—
following placental transfusion, 7
in the infant of the diabetic mother, 259
Hyperglycaemia, maternal, 252-253
Hyperinsulinism, fetal, 252-253
Hyperlipidaemia, screening for in the newborn, 278-279
Hyperlysinaemia, 281
Hyperosmolality in the newborn, 22-28
feeds inducing, 22-24
infusions inducing, 24-26
management of, 26-28
pathophysiology of, 26
Hyperparathyroidism—
disturbed electrolyte metabolism and, 136-137
maternal, associated with neonatal hypoparathyroidism, 138
Hyperphenylalaninaemia, screening for in the newborn, 273-274
Hyperpotassaemia, in the infant of the diabetic mother, 259
Hyperviscosity syndromes, in the neonate, 7
Hypoaldosteronism, 16-18
congenital, 17
pseudo-, 17
Hypocalcaemia, in the infant of the diabetic mother, 259
Hypoglycaemia—
maternal, 253-255
homeostasis, 254
symptoms of, 254-255
screening for in the newborn, 279
Hypomagnesaemia, in the infant of the diabetic mother, 259
Hypo-osmolality in the newborn, 28-29
Hypoparathyroidism—
congenital (idiopathic), 137
disturbed electrolyte metabolism and, 136-137
maternal, associated with neonatal hyperparathyroidism, 138
Hypothyroidism, screening for in the newborn, 276-277
Hypoxaemia, in the neonate, 61-63

IDIOPATHIC hypoparathyroidism, 137
Idiopathic neonatal tetany, 138-139
Idiopathic respiratory distress syndrome (IRDS), blood volume changes and, 6-7
Iminoglycinuria, 280
Immunoassays, for metabolic screening of the newborn, 272
Infection, in the infant of the diabetic mother, 259
Infusion practice, for parenteral nutrition, 211
Insulin—
in infants of diabetic mothers, 247-248
anencephalic studies, 248
pancreatic islet content, 247
response to stimulation, 247-248
in the neonate, 222-227
Intravenous feeding of the newborn, **191-219**
Intraventricular haemorrhage (IVH), 103-104
Iron, metabolism of in the newborn, **149-174**
content of food, 159-160
deficiency, 162, 164-170
distribution of, 149-150
enzymatic function of, 149-150
excretion of, 163
factors affecting absorption, 160-162
factors influencing content of, 151-153
metabolic function of, 149-151
postnatal changes, 158-159
relationship to maternal nutrition, 153-155
requirements of, 159
storage of, 150-151, 163
transport of, 150-151, 155-158, 162-163
Isoimmunisation, rhesus, 7-8
Isoniazid, in the fetus and newborn, 185

Isotonic dehydration in the newborn, 30
Isovaleric acidaemia, 282

JAUNDICE—
breast milk, 116-119
of the newborn—
bilirubin metabolism in relation to, **107-122**
pathogenesis of in relation to therapy, 107-109

KERNICTERUS, free bilirubin and, 119-120
Kidneys, immaturity of affecting nutritional status, 194-195

LACTIC acidaemia, 282-283
Lecithin/sphyngomyelin (L/S) ratio, in infants of diabetic mothers, 245
Leucine, screening for in the newborn, 275

MAGNESIUM metabolism, in the perinatal period, **123-147**
disturbed, 135-143
classification of, 136
clinical management of, 135-136
effects of prematurity and intrauterine growth retardation, 140-141
from inherent defects in parents, 136-137
impairment of placental function and, 140
intrauterine mineral status and, 137-138
nutritional deficiency from, 138-140
treatment of, 141-142
in infants of diabetic mothers, 246
neonatal requirements, 131
normal maternal requirements, 123-135
amniotic fluid concentrations of, 125
blood concentrations of, 123-124
fetal content of, 125-130
hormonal, 131-135
placental concentrations of, 124
transplacental movement of, 125
Maple syrup urine disease, 282
Marrow, erythropoietic activity in, 162
Marrow replacement, thrombocytopenia from, 100
Metabolic screening of the newborn, **265-288**
Metabolism—
as studied in the neonate by exchange transfusion, **221-235**
electrolyte, in the newborn, **3-37**
fluid, in the newborn, **3-37**
Methylmalonic acidaemia, 282
Microbiological methods, for metabolic screening of the newborn, 271
Minerals—
availability as nutrient materials, 208
requirements of for parenteral nutrition, 198-200
Mucopolysaccharides, screening of in the newborn, 273
Muscle, fetal, electrolyte content of, 130
Myoglobin, role of iron in, 150

NATRURIETIC hormone, in neonatal electrolyte metabolism, 18
Neuroblastoma, screening test for, 283-285
Nitroprusside test, for screening in the newborn, 273
Nutrition—
iron, relationship of maternal to fetal, 153-155
parenteral, *see under* Parenteral nutrition
Nutritional deficiency, effects of on the neonate, 138-140
Nutritional requirements of the neonate, in hyaline membrane disease, 67

ORNITHINE, in the newborn, 279-280
Osmolal changes in the newborn, 22
Oxygen, in the treatment of respiratory dysfunction, 73-76
Oxytocin, in relation to newborn jaundice, 119

PANCREATIC secretions, effects of bicarbonate content of on iron absorption, 162
Parathyroid—
congenital absence of, 137
hypoplasia of, 137
Parathyroid hormone (PTH)—
during pregnancy, 131-132
in the neonate, 231-232
in infants of diabetic mothers, 250
Parenteral nutrition, 191-214
available nutrients for, 202-210
infants requiring, 191-192
management of, 211-214
biochemical assessment, 213-214
clinical assessment, 213
metabolic effects of, 214-217
physiological background to, 192-196
immaturity of organ function, 194-196
nutrient reserves, 192-194
relevance of, 214-217
requirements in, 196-202
amino acids, 197-198
carbohydrates, 197
fat, 197

Parenteral nutrition, 191-214—*continued*
minerals, 198-200
vitamins, 200-202
water, 196-197
Penicillin—
in the fetus and newborn, 182-183
semi-synthetic, 183
Peroxidase, role of iron in action of, 150
Phenobarbitone, effects of administration of to the newborn, 109-111
Phenylketonuria (PKU), screening for in the newborn, 273-274
Phosphorus load, from feeding, 141-142
Phosphorus metabolism, in the perinatal period, **123-147**
disturbed, 135-143
classification of, 136
clinical management of, 135-136
effects of prematurity and intrauterine growth retardation, 140-141
from inherent defects in parents, 136-137
impairment of placental function and, 140
intrauterine mineral status and, 137-138
nutritional deficiency from, 138-140
treatment of, 141-142
in infants of diabetic mothers, 247
neonatal requirements, 131
normal maternal requirements, 123
amniotic fluid concentrations, 125
blood concentrations, 123-124
fetal content, 125-130
hormonal, 131-135
placental concentrations, 124
transplacental movement of, 125
Phototherapy, effects of in the newborn, 111-116
clinical trials, 112-113
Phytates, effects of on iron absorption, 162
Placenta—
concentrations of electrolytes in, 124
multilobular, 166
Plasma factor deficiency, congenital, 167
Platelet function disorder, thrombocytopenia and, 100
Platelets, 95, 96
Poikilothermy, in the newborn, 39-40
Polymixins, in the fetus and newborn, 185
Potassium metabolism in the newborn, 22
in infants of diabetic mothers, 247
Prematurity, effects of on electrolyte metabolism, 140-141
Prolactin, in neonatal electrolyte metabolism, 21
Proline, in the newborn, 280
Propionic acidaemia, 282
Protein metabolism, in infants of diabetic mothers, 246
Pulmonary haemorrhage, 102-103
Pulmonary hypoperfusion in the neonate, 61-63
Pyruvic acidaemia, 282-283

RADII, absent, thrombocytopenia and, 100
Reducing sugar tests, for screening the newborn, 272
Renal blood flow, 11
Renal function, 9-15
effect of blood volume on in the neonate, 8
in the fetus, 9-11
in the sick neonate, 14-15
postnatal, 11-15
Renin, in neonatal electrolyte metabolism, 15-18
Respiratory distress in the neonate, metabolic consequences of, 60-69
acid—base balance disturbances, 61-64
blood proteins and, 64
blood volume and, 64
body fluid metabolism, 65
body temperature, 65-67
CNS damage, 68-69
disseminated intravascular coagulation, 68
nutritional requirements, 67
Respiratory distress syndrome (RDS) in the neonate, metabolic changes in, **55-87**
Respiratory dysfunction, treatment of, 73-78
correction of acidosis, 76-78
priorities in, 73
use of oxygen in, 73-76
Resuscitation, of infants of diabetic mothers, 258
Rhesus isoimmunisation, 7-8
Rickets, fetal, 139-140

SCREENING, metabolic, of the newborn infant, **265-288**
choice of tests for, 267-268
cost of, 268-269
criteria for selection for, 266-267
effect of on gene pool, 269
for congenital infections, 285
for specific conditions, 273-279
informed consent for, 268
methods for, 269-273, 283-285
chromatographic, 271
enzymic, 271
immunoassay, 272
laboratory, 272-273
microbiological, 271
protein assay, 271
timing of sampling for, 269-270
types of blood sample for, 270-271
selection versus universal, 267
service versus research, 267-268

Sedatives, in the fetus and newborn, 186-187
Shivering, thermogenesis by in the newborn, 51
Sickle cell disease, screening for in the newborn, 278
Sodium—
  excretion of in the newborn, 11-13
  metabolism of in the newborn, 22
  retention of in the newborn, 11-13
Summit metabolism in the newborn, 48-49
Surfactant—
  and surfactant deficiency in hyaline membrane disease, 56-58
  in hyaline membrane disease—
    endogenous induction of, 72
    exogenous induction of, 70-72
Synalbumin, in infants of diabetic mothers, 249

TEMPERATURE in the newborn—
  changes during blood transfusion, 232-233
  disturbance of, **39-54**
  regulation of, **39-54**
Tetany, idiopathic neonatal, 138-139
Thermal environment of the newborn, 51-52
Thermal neutrality in the newborn, 42-44
Thermogenic response, variations of in the newborn, 49-51
Thermogenesis, transition in the neonate to shivering-induced, 51
Thermoregulation in the newborn, 40-42
  responses to a cool environment, 45-47
  responses to a hot environment, 44-45
  thermal neutrality, 42-44
Third and fourth pharyngeal pouch syndrome, 137
Third hormone, 18
Thrombocytopenia, in the newborn, 167
  conditions characterised primarily by, 99-100
  immune disorders and, 99-100
  induced by drugs, 100
  induced by infection, 100
  isolated, 99
Thyroxine in the neonate, 230-231
  in infants of diabetic mothers, 250
Thyrotrophin (TSH), in the neonate, 230-231
Tissue hypoxia, in the neonate, 63-64
Transfusion, exchange, *see under* Exchange transfusion
Transient haemorrhagic disease of the newborn, 167
Triiodothyronine, in the neonate, 230-231
Twin, transfusion to twin, 164-165
Tyrosine, screening for in the newborn, 274

UMBILICAL cord—
  aneurysm of, 165
  haematoma of, 165
  rupture of, 165
  rupture of anomalous vessels of, 165-166
  varix of, 165
Umbilicus, bleeding from, 166
Urine, of the newborn, chromatography of, 280-281

VASCULAR fragility, 89, 95
Vascular permeability, 89, 95
Vasopressin—
  inappropriate secretion of in the neonate (SIADH), 19-20
  in neonatal electrolyte metabolism, 19-20
Vitamin D, during pregnancy, 132-134
Vitamin K-dependent factors, deficiency of, 97-98
Vitamins—
  availability as nutrient materials, 208
  requirements of for parenteral nutrition, 200-202

WATER—
  in the neonate—
    conservation of, 13-14
    excretion of, 13-14
  requirements of for parenteral nutrition, 196-197
Wiskott—Aldrich syndrome, thrombocytopenia in, 100

Index

Note: Page numbers of article titles are in **boldface** type.

ADIPOSE tissue—
  cellularity—
    in human obesity, **229-311**
    in relation to age of onset of obesity, 303-307
    in relation to severity of obesity, 301-303
    methods of studying, 300-301
    results of studies of, 301-307
  effects of hyperinsulinaemia on, 348-349, 354
Adrenal gland, in anorexia nervosa, 525
Amenorrhoea, following small bowel bypass, 490-491
Amphetamine, in suppression of appetite, 456-461
  mechanism of action of, 456-457
  metabolism of, 459
  pharmacology of, 458-459
    cardiovascular effects, 458-459
    effects on the central nervous system, 458
    metabolic effects of, 459
Anaemia, following small bowel bypass, 495
Animal obesity—
  evolution of, 337-338
  hyperinsulinaemia of, 343-354
    early consequences of, 346-351
    late consequences of, 351-354
    role of hypothalamus in, 343-344
  overactive pancreatic β-cells in, 344-346
  resistance to insulin in, 354-357
    due to changes in receptors, 355-356
    intracellular alterations and, 356-357
  role of the hypothalamus in the hyperphagia of, 339-343
    induction by experimental lesions, 339-342
    induction by natural lesions, 342-343
Anoretic drugs—
  clinical use of, 459-461
  effectiveness of, 459-460
  safety of, 460-461
Anorexia nervosa—
  activity in, 521
  aetiology of, 532-533
  attitude towards food in, 520
  attitude towards weight in, 520
  behavioural aspects of, **517-535**
  clinical history of, 519-520
  diagnosis of, 517-521
  hypothalamic aspects of, **517-532**
    carbohydrate metabolism, 531-532
    releasing hormone actions, 530-531
    thermoregulation, 527-529
    water conservation, 529
  pathogenesis of, 532-533
  pituitary-end organ function in, 521-527
    adrenal gland, 525
    gonadal axis, 525-527
    growth hormone, 521-522
    prolactin, 523
    thyrotropin, 523-525
Appetite—
  effects of exercise on, 438
  effects of smoking on, 391-392
Arthritis, following small bowel bypass, 497
ATP—
  inefficient generation of, 387
  inefficient utilisation of, 388

BALANCED diets, 424
Biguanides, in treatment of obesity, 475
Blood pressure, following small bowel bypass, 489
Body composition, effects of exercise on, 432-438

CALORIGENIC drugs, in suppression of appetite, 463-471
  dinitrophenol, 470
  growth hormone, 471
  thyroid hormones, 463-470
Carbohydrate-free diets, 425
Carbohydrate metabolism—
  following small bowel bypass, 489-490
  in anorexia, nervosa, 531-532
Cardiovascular disease—
  obesity and, **367-375**
  risk of, 372-373
Cholelithiasis, following small bowel bypass, 494
Cholesterol metabolism, obesity and, 315-317
Congestive heart failure, following small bowel bypass, 490

DIABETICS, obese, 381-382
Dinitrophenol, as a calorigenic drug, 470
Dyspnoea, following small bowel bypass, 490

ELECTROLYTE imbalance, following small bowel bypass, 496
Energy balance in experimental obesity, 383-392
  clinical implications of variations in thermogenesis, 392
  effects of smoking on, 391-392
  mechanisms of dietary-induced thermogenesis, 386-391
    change in specific dynamic action in, 388-389
    changes in thyroid function in, 389-391
    effect of mental state in, 389
    inefficient generation of ATP in, 387
    inefficient utilisation of ATP in, 388
    ionic pump activity in, 389
    uncoupling of oxidative phosphorylation in, 387-388
Energy stores, 397-398
Exercise—
  and weight stability, 434-436
  duration and intensity of required for weight loss, 433-434
  endocrine effects following, 441-443
    insulin concentrations, 443-444
  in the prevention of obesity, 444-447, 448-449
  in the treatment of obesity, **431-453**
  metabolic effects following, 432-444
    effects on appetite regulation, 438
    effects on body composition, 432-438
    effects on cellular metabolism, 443
    effects on energy substrate concentrations, 438-441
  psychological aspects of, 449
  risks from, 449

FAT absorption, drugs affecting, 476
Fat mobilisation, increase of in treatment of obesity, 471-475
Food intake—
  in man, **503-516**
    behaviour patterns of, 506-512
    modifications of eating behaviour, 512-514
  normal regulation of in animals, 339
Framingham Study, **367-375**
  body weights in, 368-369
  methods used in, 367-368
  relation of weight to health, 369-372

GASTROINTESTINAL hormones, in suppression of appetite, 461-463
Glucagon, role of in obesity, 328
Gluconeogenesis, during starvation, 402-405, 406-407
Glucose absorption, drugs affecting, 475
Glycogenolysis, during starvation, 400-402
Gonadal axis, in anorexia nervosa, 525-527
Growth hormone (GH)—
  as a calorigenic drug, 471
  in anorexia nervosa, 521-522

HUMAN chorionic gonadotropin, use of to increase fat mobilisation, 471-475
  chemistry of, 472-473
  clinical use of, 473-475
  physiology of, 472-473
Hunger, 421-424
Hydroxycitrate, in treatment of obesity, 476
Hyperinsulinaemia—
  early consequences of, 346-351
    on adipose tissue, 348-349
    on liver metabolism, 347-348
    on muscle metabolism, 349-351
  late consequences of, 351-354
  role of hypothalamus in, 343-344
Hyperlipidaemia, following small bowel bypass, 488-489
Hyperphagia, role of hypothalamus in, 339-343
Hypothalamus—
  in anorexia nervosa, 527-532
  role of in hyperinsulinaemia, 343-344
  role of in hyperphagia, 339-343
    experimental lesion effects, 339-342
    natural lesion effects, 342-343

INFERTILITY, following small bowel bypass, 490-491
Insulin, 320-327
  effect of exercise on, 443-444
  resistance to in animal obesity, 354-357
    due to changes in receptors, 355-356
    intracellular alterations and, 356-357
  role of in obesity, **313-335**
Intussusception, following small bowel bypass, 494-495
Ionic pump activity, in thermogenesis, 389

KETOSIS, during starvation, 405-406, 406-407
Kidney, role of in starvation, 409

LIPID metabolism, changes of in obesity, **313-335**
  cholesterol metabolism, 315-317
  plasma lipids, 313-315
  triglyceride metabolism, 317-319

Liver—
failure, following small bowel bypass, 492-494
metabolism, effects of hyperinsulinaemia on, 347-348, 354

MEAL patterns, effects on nitrogen balance, 420
Muscle—
effects of hyperinsulinaemia on, 349-351, 354
role of during starvation, 408-409

NEPHROLITHIASIS, following small bowel bypass, 496-497

OBESITY—
adipose tissue cellularity in, **299-311**
age of onset of obesity in relation to, 303-307
severity of obesity in relation to, 301-303
animal, *see* animal obesity
cardiovascular disease and, **367-375**
risk of, 372-373
changes in lipid metabolism in, **313-335**
cholesterol metabolism, 315-317
plasma lipids, 313-315
triglyceride metabolism, 317-319
exercise in the prevention of, 444-447, 448-449
exercise in the treatment of, **431-453**
experimental, See also Animal obesity—
anatomical changes in, 378
clinical implications of, **377-395,** 381-382
consequences of, 378-382
endocrine changes in, 378-381
energy balance in, 383-392
hormonal basis of, **337-365**
metabolic basis of, **337-365**
metabolic changes in, 378-381
food intake behaviour, implications of for treatment of obesity, **503-516**
Framingham Study, **367-375**
hyperplastic, effect of exercise on, 447
mechanisms of, 334
morbid, small bowel bypass in treatment of, **481-502**
pharmacological approach to treatment of, **455-479**
action at gastric level, 476
affecting appetite, 456-463
calorigenic drugs, 463-471
increase of fat mobilisation, 471-475
interference with intestinal absorption, 475-476
role of glucagon in, 328
role of insulin in, **313-335**
spontaneous, 381
thyroid function in, 463-470
treatment of, **431-453, 455-479, 481-502,** 504-505
Oxidative phosphorylation, uncoupling of, 387-388

PANCREAS, overactivity of β-cells of in animal obesity, 344-346
Pancreatitis, following small bowel bypass, 495
Pickwickian syndrome, 489
Pituitary function, in anorexia nervosa, 521-527, 530-531
Plasma, lipids of and obesity, 313-315
Potassium, requirement for in water diet, 418-420
Progesterone, in the treatment of problems related to obesity, 476
Prolactin, in anorexia nervosa, 523
Protein diets—
effects of meal patterns, 420
effects of restrictive diets, **417-430**
effects on hormone levels, 420-421
effects on weight, 425-428
hunger with, 421-424
potassium content of, 418-420
quality of, 417-418
quantity of, 417-418
vitamin content of, 418-420

SMALL bowel bypass, in the treatment of morbid obesity, 481-502
beneficial results of, 487-491
on blood pressure, 489
on carbohydrate metabolism, 489-490
on congestive heart failure, 490
on dyspnoea on exertion, 490
on hyperlipidaemia, 488-489
on infertility, 490-491
on stasis ulcerations, 490
pickwickian syndrome, 489
psychosocial aspects, 491
complications of, 491-497
anaemia, 495
arthritis, 497
cholelithiasis, 494
electrolyte imbalance, 496
intussusception, 494-495
liver failure, 492-494
nephrolithiasis, 496-497
pancreatitis, 495
vitamin imbalance, 495
history of, 481-484
operative technique for, 487
patient population, 486

patient selection for, 484-486
preoperative evaluation of, 486
problems of, 498
revision of, 497
take-down of, 497
Smoking, effects of on appetite, 391-392
Specific dynamic action, thermogenesis from, 388-389
Starvation in man, **397-415**
available energy stores, 397-398
clinical phenomena in, 409-411
brain function changes, 410
metabolic rate, 411
metabolic sequelae, 410-411
weight loss, 409-410
partial, 412
carbohydrate supplementation, 412
protein supplementation, 412, **417-430**
phases of, 398-407
diminishing gluconeogenesis and increasing ketoacid consumption, 406-407
gastrointestinal, 398-400
gluconeogenesis, 402-405
glycogenolysis, 400-402
ketosis, 405-406
role of kidney in, 409
role of muscle in, 408-409
Stasis ulcerations, 490

THERMOGENESIS—
clinical implications of variations in, 392
dietary-induced, **377-395**
mechanisms of, 386-391
effect of smoking on, 391-392
Thermoregulation, in anorexia nervosa, 527-529
Thyroid—
function—
changes of in thermogenesis, 389-391
in anorexia nervosa, 523-525
hormones of in treatment of obesity, 463-470
biological effects of, 465-466
clinical uses of, 466-470
Thyrotropin (TSH), in anorexia nervosa, 523-525
Triglyceride metabolism, obesity and, 317-319

VITAMIN—
imbalance, following small bowel bypass, 495
requirements of in water diet, 418-420

WATER conservation, in anorexia nervosa, 529
Weight—
effects of restrictive diets on, 425-428
in relation to health, 369-372

NDEX

392

a, 527-

391
63-470

a, 523-
17-319

ypass,
20

sa, 529
8

Index

Note: Page numbers of article titles are in **boldface** type.

ABSORPTIVE capacity, effects of diet and luminal contents on, 642
Acid-base disturbances in red cell 2,3-diphosphoglycerate, 658-659
Acromegaly, and glucose turnover, 794
Acute myocardial infarction, 703-718
Adrenal tumours, hypoglycaemia and, 773
Alcohol infusion test, 812
Alcoholic liver disease, animal model for, 694-695
Arterial disease, effect of on tissue metabolism, 722-723

BLOOD, stored, 2,3-diphosphoglycerate in, 659-660
Blood glucose
  and glucose kinetics, in trauma, 731-736
  antilipolytic effect of insulin and regulation of, 569-572
  measurement of, 805-810
  overnight fasting, 806-807
  random, 806
  membrane transport, effect of insulin and, 572
  regulation of, 543-574
  roles of insulin in regulation of the, 568-574
Blood lactate/pyruvate ratio, use of as indicator of tissue hypoxia, 615-616
Blood metabolites, investigations into, 817-818
Brancher deficiency, 592

CANCER patients, and glucose turnover, 792-794
Carbohydrate absorption, drugs and, 643-644
Carbohydrate carriers, 639
Carbohydrate digestion and absorption—
  clinical summary and implications for therapy, 644-645
  disorders of, **627-645**
Carbohydrate feeding, blood glucose and, 544
Carbohydrate intolerance, 703-705, 718
  as reflection of general metabolic changes, 705, 709-711, 718-722
Carbohydrate metabolism—
  disorders of, in red blood corpuscle, **651-670**
  hormones of, 687-694
  local changes in, 712-713
  selected tests of, 805-818
Carbohydrate metabolism in cardiovascular disease, **703-724**
Carbohydrate metabolism in liver disease, **675-696**
Carbohydrate metabolism in man, use of isotope turnover techniques in the study of, **783-800**
  experimental techniques, 783-791
  glucose turnover in altered endocrine or metabolic states, 792-796
  glucose turnover in normal man, 791-792
  isotope turnover techniques in elucidating factors affecting glucose haemostasis, 796-800
Carbohydrate metabolism in trauma, **731-744**
Carbohydrate metabolism in vivo: regulation of blood glucose level, **543-574**
Carbohydrates, dietary, 627
Carcinoid tumours, 774
Cardiovascular disease, carbohydrate metabolism in, **703-724**
Carriers, absorption membrane, 639
Catecholamines, cardiovascular disease and, 709-710, 722
Colonic function, 641-642
Congenital lactase deficiency, 634
Continuous infusion technique, 748-787
Corticosteroids, 691

DEBRANCHER deficiency, 589-592
2-Deoxyglucose test, 814
Diazoxide infusion test, 811
Dietary carbohydrates, 627
2,3-Diphosphoglycerate, 653-660
  and altitude, 659
Disaccharidase deficiencies—
  primary, 634-637
  secondary, 637-638
Disaccharidases—
  classification and characterisation of intestinal mucosal, 631-632
  location of intestinal mucosal, 629-631
Disaccharide digestion, 629-634
  biochemistry and in vitro studies, 629-632

Disaccharide digestion (*continued*)
human perfusion studies of, 634
Disaccharide digestion in vivo, 632-634
Disaccharides, structure of, 629
Drugs and carbohydrate absorption, 643

ENCEPHALOMYELOPATHY, subacute necrotising, 623
Endocrine pancreas, sympathetic control of, 736-738
Epithelial tumours, 772-774
Ethanol and glucose metabolism, 798-799
Exercise—
and glucose turnover, 794-795
prolonged, and glucose, 544, 546-547
Extrapancreatic neoplasms, 769-776

FAST, prolonged, as test for hypoglycaemia, 807
Fasting, and glucose turnover, 795-796
Fatty acid mobilisation—
regulation of in the intact animal, 552-553
regulatory role of ketone bodies on, 553-555
Fatty acid oxidation, regulation of gluconeogenesis by, 561
Fatty acids—
free, 709
non-esterified and the glucose system, 800
Fish insulin test, 812
Fructose intolerance, hereditary, 603-607
Fructose metabolism, 599-602
disorders of, **599-610**
Fructose tolerance test, 816-817
Fructose transport, 640
Fructose-1, 6-diphosphatase deficiency, 607-610
Fructosuria, essential, 602

GALACTOSE intolerance, familiar fructose and, 610
Galactose metabolism, tests of, 816
Galactose tolerance test, 816
Glucagon, 691-692, 710-711
Glucagon test, intravenous, 814-815
Gluconeogenesis—
altered protein economy and reflection of, 738-740
in liver and kidney cortex, 560
significance of alanine as a precursor for, 562-566
Glucose, and liver disease, 679-681
Glucose flow, heat production and nitrogen loss, 740-741
Glucose—galactose carrier, 639-640
Glucose kinetics, blood glucose and, 731-736
Glucose-6-phosphatase deficiency, 622
Glucose-6-phosphate dehydrogenase deficiency, 661, 664
Glucose production, regulation of, 558-568
Glucose therapy in myocardial infarction, 715-718
Glucose tolerance test, five-hour oral, 807-810
Glucose turnover—
in altered endocrine or metabolic states, 792-796
in normal man, 791-792
Glucose uptake, role of the liver in regulation of, 557-558
Glucose utilisation—
conditions affecting, 543-548
effects of fatty acids and ketone bodies on, by other tissues, 551
effects of ketone body oxidation on, 551
glucose—fatty acid—ketone body cycle in, 549-552
regulation of, 548-558
Glutamine, as a gluconeogenic precursor, importance of, 565-566
Glycogen metabolism, disorders of, **579-596**
Glycogen molecule, 579
Glycogen storage diseases, 582-596
low molecular weight, 592-593
recognition of, 595-596
Glycogen synthesis and degradation, 579-582
Glycolytic pathway, defects in, 664-669
Growth hormone, 692
Gut changes, neonatal, 642

HEPATIC carcinoma, primary, 772
Hepatic fructose 1,6-diphosphatase deficiency, 622
Hepatic glycogen storage with progressive degeneration of the central nervous system, 595
Hepatic phosphorylase activity, mechanism of control of, 558-560
Hormone receptors, and liver disease, 695
Hormones—
diabetes and intestinal absorption, 642-643
regulation of glucogenesis by, 561
Hypoglycaemia—
caused by tumours, treatment for, 776
causes other than insulinomas, **769-780**
aetiology of tumour, 774-776
alcohol-induced, 779-780
diagnostic procedures, 759-763
insulin secreting tumours, **747-763**
symptoms, 757-758
therapy for, 763
Hypoglycaemia, reactive, 776-779
glucose-induced, 777-779
Hypoxia and the red cell 2,3-diphosphoglycerate, 656-657

INSULIN, 687, 689-690
anabolic role of, 572
in obesity, 572-574
homeostatic role of, 569-572
roles of in regulation of blood glucose level, 568-574
secretion of, 752-757
Insulin and tolbutamide, and glucose metabolism, 796-797
Insulin secreting tumours, glycaemia and, **747-763**
Insulin suppression tests, 812
Insulin tolerance test, 812-814
Insulinoma cells, proinsulin and insulin contents, 752-755
Insulinomas, structure and cellular origin, 747-752
Intestinal sampling, 633
Intravenous glucagon test, 814-815
Intravenous tolbutamide tolerance test, 815
Isomaltases, 632
Isotope tracers, stable, 791
Isotope turnover techniques, **783-800**
problems of interpretation, 790-791
in elucidating factors affecting glucose homeostasis, 796-800

KETOGENESIS, regulation of the rate of, 555-556
Kidney cortex, glucogenesis in, 560

LACTASE deficiency—
congenital, 634
diagnosis of primary acquired, 635-637
primary acquired, 635
Lactase retainers and mucosal damage, 638
Lactases, 632
Lactate metabolism—
and hyperventilation, 623-624
disturbances of, 615-624
Lactic acid, biochemical and physiological aspects of, 613-615
Lactic acid metabolism, disorders of, **613-624**
Lactic acidosis, 616-623
associated with myopathy, 623
of infancy and childhood, 622-623
recurrent, of infancy, with psychomotor retardation, 622
type B, 616-622
Lactose tolerance test, 817
Leigh's syndrome, 623
Leucine tolerance test, 815-816
Leucocyte galactose-1-phosphate uridyl transferase test, 816
Lipid changes, local, and cardiovascular disease, 713
Liver—
in normal man, 675-679
regulation of gluconeogenesis in the, 560-562
Liver and muscle glycogenosis, 595
Liver cell, regulation of gluconeogenesis by energy status of the, 561
Liver cortex, gluconeogenesis in, 560
Liver disease, 679-694
carbohydrate metabolism in, **675-696**
hepatotrophic factors, 695
hormone receptors, 695
in the fasting state, 679-684
in the fed state, 684-687
Liver phosphorylase deficiency, 594
Liver phosphorylase kinase deficiency, 595

MALTASES, 631
Man, normal—
in the fasting state, 675-677
in the fed state, 677-679
liver in, 675-679
Membrane digestion, 628-629
Mesenchymal tumours, 770-772
Methylmalonic aciduria, 623
Monosaccharide absorption in vivo, 638-641
Monosaccharide transport, mechanism of, 638-640
Mucopolysaccharides, cardiovascular disease and, 721
Muscle—
effects of fatty acid oxidation on glucose utilisation by, 549-550
release of glutamine by, 564
roles of ketone bodies and branched-chain amino acids in regulation of protein degradation in, 566-568
source of alanine released by, 562-564
Muscle phosphofructokinase deficiency, 594-595
Muscle phosphorylase deficiency, 593-594
Myocardial infarction—
acute, 703-718
glucose therapy in, 715-718

NEOPLASMS, extrapancreatic, 769-776
Non-steady state systems, isotope turnover techniques and, 787-789

OBESITY—
anabolic role of insulin in, 572-574
and glucose turnover, 792

PANCREAS, carcinoma of the exocrine, 773-774

Pentose phosphate pathway, defects in, 660-664
Perfusion studies, of disaccharide digestion and absorption, 634
Peripheral vascular disease, 718-723
Phenformin and glucose metabolism, 797-798
Plasma (serum) insulin assay, 810
Plasma proinsulin and proinsulin-like components, 811
Pompe's disease, 587-589
Protein economy, altered, a reflection of gluconeogenesis, 738-740
Proinsulin, 752-757
Pyruvate kinase deficiency, 669

RECYCLING of label, in isotope turnover techniques, 790
Red cell—
  ageing of the, 653
  cell enzyme defects, 660-669
  fetal, 660
Reticulocytes, 653

SECRETION of insulin and proinsulin, 755-757
Sepsis in critically injured man, 741-744
Sex hormones, cardiovascular disease and, 721
Sorbitol, cardiovascular disease and, 721
Starch, chemistry and hydrolysis of, 628
Starch digestion, 628-629
  clinical studies of, 629
Starvation—
  prolonged and glucose, 545-548
  role of blood level of alanine in regulation of gluconeogenesis during, 565
Steady state systems, in isotope turnover techniques, 783-787
Substrate availability, regulation of gluconeogenesis by, 561-562
Sucrase, 632
Sucrase deficiency, 635
Sympathetic control of endocrine pancreas, 736-738

THYROID status and glucose turnover, 794
Tissue hypoxia, use of blood lactate/pyruvate ratio as indicator of, 615-616
Tissue metabolism, effect of arterial disease on, 722-723
Tolbutamide tolerance test, intravenous, 815
Tolerance tests, with disaccharides, 632
Tracer assay, in isotope turnover techniques, 789-790
Tracer quantity, in isotope turnover techniques, 790
Trauma, carbohydrate metabolism in, **731-744**
Trehalase, 632
Trehalase deficiency, 635

VASCULAR disease, peripheral, 718-723
von Gierke's disease, 584-587